Showing results (291-300 of 528) with videos related to
Sort By:
Pageof 53
Science (New York, N.Y.)|April 27, 2013
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibodyJason S McLellan, Man Chen, Sherman Leung, et al.Journal of Virology|October 23, 2009
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunizationCheng Cheng, Jason G D Gall, Martha Nason, et al.The Journal of Infectious Diseases|November 17, 2006
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccineBarney S Graham, Richard A Koup, Mario Roederer, et al.Journal of Virology|July 1, 2011
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01Yuxing Li, Sijy O'Dell, Laura M Walker, et al.Vaccine|February 27, 2021
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataFlor M Munoz, Jakob P Cramer, Cornelia L Dekker, et al.Mbio|December 5, 2019
Simian Immunodeficiency Virus Infection of Rhesus Macaques Results in Delayed Zika Virus ClearanceCarol L Vinton, Samuel J Magaziner, Kimberly A Dowd, et al.Vaccine|February 21, 2022
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global useErin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, et al.Contemporary Clinical Trials|August 16, 2015
Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boostJulie E Ledgerwood, Zonghui Hu, Pamela Costner, et al.Plos One|May 8, 2015
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trialJulie E Ledgerwood, Abbie R Bellamy, Robert Belshe, et al.Science (New York, N.Y.)|February 27, 2016
Structural and molecular basis for Ebola virus neutralization by protective human antibodiesJohn Misasi, Morgan S A Gilman, Masaru Kanekiyo, et al.Pageof 53